The rate of non-Hodgkin's lymphoma has nearly doubled since the ... For slow-growing lymphomas, long-term survival is common, although they cannot be cured. More aggressive tumors are more ...

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...

Non-Hodgkin lymphoma is a cancer that affects lymphocytes, a type of white blood cells in the lymphatic system. They are generally classified according to the cancer's growth rate as high grade ...

Medically reviewed by Gagandeep Brar, MD Leukemias and lymphomas are often grouped together because they are both blood-related cancers that originate in lymphocytes. However, leukemia originates in ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

The five-year relative survival rate for stage 4 Hodgkin lymphoma is 81 percent, and 64 percent for stage 4 non-Hodgkin lymphoma. Everyday Health follows strict sourcing guidelines to ensure the ...

Non-Hodgkin's lymphoma invades the brain ... but most patients relapse, and the 5-year survival rate remains inferior to that of patients over 60 years of age with DLBCL outside the nervous ...

Primary non-Hodgkin's lymphoma of the breast (PBNHL) is uncommon. There have been only a few reports of breast lymphoma in the radiology literature. In this case report, we describe mammographic ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...